PDL BioPharma, Inc. (Nasdaq:PDLI) announced that it has completed the retirement of the remaining $133.5 million in aggregate principal of the Company's 2.00% Convertible Senior Notes, due February 15, 2012 (the Notes), for $133.9 million plus interest of $1.0 million. With the completion of this redemption, no Notes remain outstanding.